Clinical trials: Schizophrenia Spectrum
Schizophrenia, Schizophreniform Disorder
rTMS in First Episode Psychosis
This study proposes to examine the application of rTMS for the treatment of cognitive dysfunction in FEP. This is an important population for study because if effective, rTMS may represent a preventative treatment for the…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- EmeraldThunder (NCT02131129)
- Testing
- rTMS
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Psychosis, Schizophrenia
CBTpro: Scaling up CBT for Psychosis Using Simulated Patients and Spoken Language Technologies
The primary objective of this grant is to develop and evaluate an Artificial Intelligence-based clinical training tool--CBTpro--to support high-quality skills training in CBT for psychosis (CBTp).
- Conditions
- Psychosis, Schizophrenia, Schizo Affective Disorder, Bipolar Disorder
- Trial name
- CBTpro (NCT05127837)
- Testing
- CBTpro
- Where
- 13 sites in United States
- Volunteers
- 601 people
- Sponsor
- University of Washington
Schizophrenia
A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia
The primary objective of this study is to investigate whether a single infusion of intravenous sodium nitroprusside (0.5 μg/kg/min for 4 hours) is superior to placebo (5% dextrose solution) at in treating positive and negative…
- Trial name
- NCT02164981
- Testing
- sodium nitroprusside
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Safety and Tolerability of Risperidone Implants
A one year, open-label, study to evaluate the safety and tolerability of risperidone implants as a maintenance treatment in patients with schizophrenia
- Trial name
- NCT02773576
- Testing
- Risperidone implant
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Braeburn Pharmaceuticals
Alzheimer's Disease, Psychosis
Treatment of Psychosis and Agitation in Alzheimer's Disease
Clinically, many patients with AD show no response or minimal response to antipsychotics for symptoms of agitation/aggression or psychosis, or they have intolerable side effects on these medications.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT02129348
- Testing
- Lithium
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to establish pharmacodynamics (PD), pharmacokinetics (PK), and adverse event (AE) profile of OPC-34712 administered to schizophrenic/schizoaffective subjects.
- Trial name
- NCT01423916
- Testing
- OPC-34712 (4mg), Moxifloxacin, OPC-34712 (12mg)
- Where
- 8 sites in United States
- Volunteers
- 218 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Staccato Loxapine in Agitation (Proof of Concept)
The purpose of this study is to assess efficacy and safety of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients.
- Trial name
- NCT00369577
- Testing
- Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Alexza Pharmaceuticals, Inc.
Metabolic Evaluation, Cardiac Complications
Metabolic and Clinical Effect of Alpha-lipoic Acid Administration in Schizophrenic Subjects
The therapeutic use of ALA in schizophrenia has recently been investigated in human populations. A case series explored the effiacy of ALA as a novel agent to treat antipsychotic-induced obesity, at a dose of 1200 mg/d (range…
- Trial name
- NCT06787781
- Testing
- Alpha Lipoic Acid
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- University of Messina
Schizophrenia Spectrum & Other Psychotic Disorders
PACT for Individuals With Serious Mental Illness
People with serious mental illness have difficulty making good use of primary care, and die, on average, years earlier than others in the population.
- Trial name
- SMI-PACT (NCT01668355)
- Testing
- Patient Aligned Care Team (PACT)
- Where
- 3 sites in United States
- Volunteers
- 331 people
- Sponsor
- VA Office of Research and Development
Transcranial Direct Current Stimulation, Smoking, Cigarette
tDCS and Cognitive Training Intervention for Chronic Smokers With Schizophrenia
This study is being done to develop new methods to help smokers with schizophrenia to successfully reduce their smoking and/or quit. This is not a treatment study, but will help find new techniques to create better treatments.
- Conditions
- Transcranial Direct Current Stimulation, Smoking, Cigarette, Schizophrenia
- Trial name
- TACTICSS (NCT03588728)
- Testing
- Transcranial Direct Current Stimulation, Cognitive Remediation (CR)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pittsburgh
Psychotic Disorders
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
This study will test the effectiveness of two different treatments for children and adolescents who have gained weight on their antipsychotic medications.
- Trial name
- IMPACT (NCT00806234)
- Testing
- Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Johns Hopkins University
Schizophrenia
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
The purpose of the this trial is to evaluate the efficacy, safety, and tolerability of an intramuscular (IM) depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia The trial is designed into…
- Trial name
- ASPIRE (NCT00706654)
- Testing
- Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg
- Where
- 98 sites in United States, Austria and 13 more
- Volunteers
- 937 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics
This multicenter study assessed the effects of 24 weeks of basmisanil treatment on cognition and functioning of stable schizophrenia participants treated with antipsychotics.
- Trial name
- NCT02953639
- Testing
- Basmisanil
- Where
- 37 sites in United States
- Volunteers
- 214 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia, Aging
Functional Rehabilitation for Older Patients With Schizophrenia
Aging and psychosis are major priority areas for VA. This project is a continuation of a Merit Review Program, in which we developed, manualized and conducted randomized controlled trials of a novel psychosocial rehabilitation…
- Trial name
- FROPS (NCT00712075)
- Testing
- CBSST+PDA, Cognitive Behavioral Social Skills Training, PDA-only
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia
Long-Term Study of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.
- Trial name
- NCT01626872
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 254 people
- Sponsor
- Tanabe Pharma Corporation
Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Infant Development
Maternal Adversity, Vulnerability and Neurodevelopment
Maternal Adversity Vulnerability and Neurodevelopment (MAVAN) project is a prospective community-based, pregnancy and birth cohort of Canadian mother-child dyads.
- Conditions
- Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Infant Development, Infant Behavior
- Trial name
- MAVAN (NCT03434457)
- Where
- Canada
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Schizophrenia, Schizoaffective Disorder
An Integrated Program for the Treatment of First Episode of Psychosis
The purpose of this study is to determine how services should be provided to reduce symptoms and improve life functioning for adolescents and adults who have been recently diagnosed with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Brief Psychotic Disorder
- Trial name
- RAISE ETP (NCT01321177)
- Testing
- Integrated Treatment, Community Care
- Where
- 33 sites in United States
- Volunteers
- 404 people
- Sponsor
- Northwell Health
Schizophrenia, Cognition
Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic
This is a study of the effects of tDCS on smoking, craving for cigarettes, cognition, and psychiatric symptoms in schizophrenic patients who are current smokers or have a history of regular cigarette smoking.
- Conditions
- Schizophrenia, Cognition, Cigarette Smoking
- Trial name
- TDCSSCHIZ (NCT02128919)
- Testing
- tDCS
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia
Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188) relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.
- Trial name
- NCT00694707
- Testing
- Cariprazine, Risperidone
- Where
- 65 sites in United States, India and 3 more
- Volunteers
- 732 people
- Sponsor
- Forest Laboratories
Schizophrenia
Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
The study evaluates the long term safety and efficacy of SM-13496 in patients with schizophrenia.
- Trial name
- NCT01614912
- Testing
- SM-13496
- Where
- 4 sites in Japan, Malaysia and 2 more
- Volunteers
- 284 people
- Sponsor
- Sumitomo Pharma Co., Ltd.